An
array of homogeneous glycans representing all the major carbohydrate
structures present in the cell wall of the human pathogen Mycobacterium tuberculosis and other mycobacteria has been
probed with a panel of glycan-binding receptors expressed on cells
of the mammalian innate immune system. The results provide an overview
of interactions between mycobacterial glycans and receptors that mediate
uptake and survival in macrophages, dendritic cells, and sinusoidal
endothelial cells. A subset of the wide variety of glycan structures
present on mycobacterial surfaces interact with cells of the innate
immune system through the receptors tested. Endocytic receptors, including
the mannose receptor, DC-SIGN, langerin, and DC-SIGNR (L-SIGN), interact
predominantly with mannose-containing caps found on the mycobacterial
polysaccharide lipoarabinomannan. Some of these receptors also interact
with phosphatidyl-myo-inositol mannosides and mannose-containing
phenolic glycolipids. Many glycans are ligands for overlapping sets
of receptors, suggesting multiple, redundant routes by which mycobacteria
can enter cells. Receptors with signaling capability interact with
two distinct sets of mycobacterial glycans: targets for dectin-2 overlap
with ligands for the mannose-binding endocytic receptors, while mincle
binds exclusively to trehalose-containing structures such as trehalose
dimycolate. None of the receptors surveyed bind furanose residues,
which often form part of the epitopes recognized by antibodies to
mycobacteria. Thus, the innate and adaptive immune systems can target
different sets of mycobacterial glycans. This array, the first of
its kind, represents an important new tool for probing, at a molecular
level, biological roles of a broad range of mycobacterial glycans,
a task that has not previously been possible.
Oligosaccharide syntheses are an important source of well-defined sugar constructs particularly needed for the evaluation of structure-activity relationships. The chemical assembly of oligosaccharides requires several building blocks, that is, glycosyl donors and acceptors, which are prepared in multistep processes and in a generally tedious and time-consuming manner. Having developed one-pot procedures meant to minimise the effort in sugar building block preparation, we tackled herein the one-pot preparation of fully protected and 2-, 3-, 4-, and 6-alcohol derivatives of d-mannose, a widely distributed monosaccharide. As a consequence of the hydroxyl group pattern of D-mannose, regioselective and stereoselective benzylidenations were developed and later seamlessly utilised as the first transformation in the one-pot procedure.
Tuberculosis, aggravated by drug-resistant strains and HIV co-infection of the causative agent Mycobacterium tuberculosis, is a global problem that affects millions of people. With essential immunoregulatory roles, phosphatidylinositol mannosides are among the cell-envelope components critical to the pathogenesis and survival of M. tuberculosis inside its host. Here we report the first synthesis of the highly complex tetraacylated phosphatidylinositol hexamannoside (Ac2PIM6), having stearic and tuberculostearic acids as lipid components. Our effort makes use of stereoelectronic and steric effects to control the regioselective and stereoselective outcomes and minimize the synthetic steps, particularly in the key desymmetrization and functionalization of myo-inositol. A short synthesis of tuberculostearic acid in six steps from the Roche ester is also described. Mice exposed to the synthesized Ac2PIM6 exhibit increased production of interleukin-4 and interferon-γ, and the corresponding adjuvant effect is shown by the induction of ovalbumin- and tetanus toxoid-specific antibodies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.